

B³ Pharma's Publications of Angiopep Drug Conjugates

• List of Publications

Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2. Journal of Neurochemistry. (2008)

Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. British Journal of Pharmacology (2008)

Identification and design of peptides as a new drug delivery system for the brain. The Journal of Pharmacology and Experimental Therapeutics. (2008)

Transport characteristics of a novel peptide platform for CNS therapeutics. J. Cell. Mol. Med. (2010)

Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1. British Journal of Cancer (2011)

Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. The Journal of Clinical Investigation. (2014)

ANG4043, a Novel Brain-Penetrant Peptide -mAb Conjugate, is Efficacious against HER2-Positive Intracranial Tumors in Mice. Molecular Cancer Therapeutics. (2015)

Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nature Reviews, Drug Discovery (2015)

ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clinical Cancer Research / Clinical Trials: Targeted Therapy (2020)

Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review. Polymers (2022)

Revealing Angiopep-2/LRP1 Molecular interaction for Optimal Delivery to Glioblastoma (GBM). Molecules (2022)

Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope ? Acta Pharmaceutica Sinica B (2023)

Old Players and new insights: unraveling the role of RNA-binding proteins in brain tumours. Theranostics (2025)

Conjugation of the brain penetrant Angiopep-2 peptide to therapeutic anti-HER2 mAb (ANG4043) and Antibody-Drug Conjugates for the treatment of HER2-Positive brain metastases

Michel Demeule¹, Gaoqiang Yang¹, Sanjoy Das¹, Christian Ché¹, Sasmita Tripathy¹, Jean-Christophe Currie¹, Anthony Régina¹, Simon Lord-Dufour¹, Serge Rivest², Paul Préfontaine², Jean-Paul Castaigne¹ and Jean E. Lachowicz¹


¹ Angiochem Inc., 201 President Kennedy Avenue, PK-2880, Montréal, QC, Canada and ²Research Center, CHU de Laval, Québec, Qc, Canada



BACKGROUND

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are uniquely capable of crossing the blood brain barrier (BBB) to treat brain diseases. These new drugs have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the BBB presents.


Angiopep Technology




Using LRP1 receptor-mediated transcytosis has a number of inherent biochemical advantages for drug transport across the BBB, including high capacity, rapid turnover, recognition of numerous ligands, and limited down-regulation. We have created peptides (Angiopeps), including Angiopep-2 (An2), using a library based on binding sequences of known LRP-1 ligands.

Angiopeps cross the BBB

Intravital imaging in mouse brain after iv Cy5.5-Angiopep injection



Immediately after injection



24hrs post-injection

Following iv administration of Cy5.5-labeled Angiopep (green) and Dextran Texas Red, yellow color in vessels results from presence of both Dextran Texas Red and Angiopep.


Dextran Texas Red is again administered iv to define blood vessels. Green Angiopep signal occurs outside of red vessels, indicating parenchymal distribution.

HER2+ Brain Metastases

- A critical unmet medical need.
- In US and Europe, 465,000 new diagnoses of breast cancer per year.
- Breast cancers overexpressing HER2 represent ~116,000 patients.
- About 33% of them will develop brain metastases.
- Herceptin does not cross the BBB and therefore can only address peripheral metastases.

ANG4043

An2-mAb-drug conjugate




ANG4043 is a chemical conjugate of the anti-HER2 mAb with the peptide Angiopep-2 (An2).

Docetaxel and maytansine were conjugated to An2-anti-HER2 mAb


An2-mAb conjugates retain their affinity for HER2 receptor

- Affinity for the HER2 receptor of the mAb is unaffected by incorporation of An2.
- The anti-proliferative potency of ANG4043 is similar to that of anti-HER2 mAb.
- ANG4043 plasma PK is also similar to native mAb.



Binding analysis of anti-HER2 and ANG4043 on BT-474 cells



Confocal microscopy analysis after 1h incubation of anti-HER2 and ANG4043 on BT-474 cells



Rate of entry into the brain (BBB permeability)




Initial transport rate (K_{in}) measured by *in situ* brain perfusion in mouse brain demonstrates that Angiopep-2 Drug Conjugates better penetrate the brain than unconjugated drugs. ANG4043 K_{in} is similar to that of An2-paclitaxel conjugate (ANG1005) which is currently in Phase 2 clinical trials for primary and secondary brain tumors.

| Anti-Cancer Drugs | BRAIN K_{in} (ml/s/g) | K_{in} Ratio (ANG vs CI) |
|---------------------------|-------------------------|----------------------------|
| Anti-HER2 | 4.8×10^{-4} | --- |
| An2-anti-HER2 (ANG4043) | 2.7×10^{-3} | 5.6 |
| Paclitaxel | 6.9×10^{-4} | --- |
| An2-Paclitaxel (ANG1005) | 4.4×10^{-3} | 6.4 |
| Doxorubicin | 2.8×10^{-4} | --- |
| An2-Doxorubicin (ANG1007) | 3.7×10^{-3} | 13 |


An2-anti-HER2-drug conjugates

Brain uptake of An2-HER2 derivatives (*in situ* brain perfusion)



Brain uptake of [¹²⁵I]-An2-anti-HER2-drug conjugates was measured by *in situ* brain perfusion and compared to that of [¹²⁵I]-ANG4043 and unconjugated [¹²⁵I]-anti-HER2 at 2 minutes. Brain capillary depletion was performed to assess the brain distribution between the brain capillaries and brain parenchyma.

Effect on cell proliferation of sensitive and resistant cells to Trastuzumab




Compilation of proliferation assay - IC₅₀ (nM)

| Compounds | Sensitive BT-474 cells | Resistant HCC-1954 cells |
|--------------------------|------------------------|--------------------------|
| Anti-HER2 | 3.6 ± 1.6 | --- |
| ANG4043 | 3.7 ± 1.7 | --- |
| An2-anti-HER2-Docetaxel | 0.6 ± 0.4 | 0.2 ± 0.1 |
| An2-anti-HER2-Maytansine | 0.9 ± 0.3 | 0.5 ± 1.1 |

Effect of ANG4043 and An2-anti-HER2-drug conjugates on BT-474/HCC1954 cell proliferation. Cancer cells were incubated for 5 days with the drugs. [³H]-Thymidine incorporation assay was then performed for IC₅₀ evaluation.

An2-drug conjugates reduce tumor size


Near Infrared Imaging of fluorescent DiR BT-474 cells



Size reduction of HER2-positive tumors with An2-mAb derivatives. BT-474 tumor cells were pre-loaded with a fluorescent dye (DiR), prior to intracranial implantation in mice. Mice were treated twice weekly with ANG4043 (15 mg/kg), An2-anti-HER2-Docetaxel (15 mg/kg) or An2-anti-HER2-Maytansine (15 mg/kg/once every 2 weeks) beginning on day 12. NiR imaging was performed on day 32.

An2-anti-HER2-drug conjugates increase mice survival

- Day 1: Intracranial implantation of BT-474 tumor cells in mice.
- Day 12: Treatments started:
 - Vehicle
 - An2-Anti-HER2-Maytansine (15 mg/kg/once every 2 weeks)
 - An2-Anti-HER2-Docetaxel (15 mg/kg/twice a week)



| Treatment | Median survival (days) | Increase (%) |
|--------------------------|------------------------|--------------|
| Vehicle | 48 | - |
| An2-anti-HER2-Docetaxel | 87 | + 81% |
| An2-anti-HER2-Maytansine | 63 | + 31% |

Early data also indicate that An2-anti-HER2-Docetaxel was better tolerated and more efficacious against BT-474 brain tumors than An2-anti-HER2-Maytansine.

Conclusions

- Two anticancer drugs (Docetaxel and Maytansine) have been conjugated to An2-anti-HER2.
- The brain-penetrant An2-anti-HER2 mAb derivatives target intracranial tumors and shrink tumor size in mice, indicating that therapeutic concentrations have been achieved in brain.
- Both new An2-anti-HER2-drug conjugates showed increases in BBB permeability when compared to unconjugated anti-HER2 mAb and in anti-proliferative activities against cell lines sensitive and resistant cell lines to Trastuzumab.
- This reduction in tumor size translates to a significant increase in survival in mice with intracranial HER2+ (BT-474 cell) tumors.
- These new brain penetrant An2-anti-HER2-drug conjugates (Docetaxel and Maytansine) improved mouse survival.
- An2-anti-HER2-Docetaxel showed the strongest potency against HER2-positive BT-474 brain tumors.
- These results suggest that the conjugation of Angiopep-2 to anti-HER2 mAb confers higher brain penetration leading to therapeutic efficacy for the treatment of HER2-positive breast cancer brain metastases and that the Angiopep-2 platform may be beneficial for targeting other CNS diseases.